Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 1/20 | 0.45 |
| ▸ | KLKB1 | P03952 | 5/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26254927 | 0.87 | KLKB1 (0.37) | UCHL1KLKB1HSP90AA1HSP90AB1 | |
| SCHEMBL26250779 | 0.87 | KLKB1 (0.43) | KLKB1KMT2ARAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL30062310 | 0.87 | LIPE (0.37) | KLKB1DGAT1 | |
| SCHEMBL15595830 | 0.83 | UCHL1 (0.51) | UCHL1HSP90AA1HSP90AB1GAAMEN1 | |
| SCHEMBL369288 | 0.81 | UCHL1 (0.49) | UCHL1HSP90AA1HSP90AB1MEN1KMT2A | |
| SCHEMBL21819814 | 0.80 | FFAR1 (0.35) | UCHL1 | |
| SCHEMBL22710333 | 0.79 | KLKB1 (0.41) | KLKB1HSP90AA1HSP90AB1GAAMEN1 | |
| SCHEMBL20371661 | 0.79 | FFAR1 (0.37) | — | |
| SCHEMBL370360 | 0.78 | UCHL1 (0.47) | UCHL1HSP90AA1HSP90AB1MEN1KMT2A | |
| SCHEMBL16870911 | 0.78 | L3MBTL1 (0.41) | NPC1RAB9AMAPTHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250100999-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2025-03-27 | — | — | US | disclosed |
| US-12122765-B2 | Methods and intermediates for preparing therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| US-20240101533-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2024-03-28 | — | — | US | disclosed |
| CN-116854630-A | Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections | 吉利德科学公司 | 2023-10-10 | — | — | CN | disclosed |
| EP-4253366-A2 | METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION | Gilead Sciences, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| US-11766434-B2 | Pyrimidinone derivatives as CDC7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-26 | — | — | US | disclosed |
| US-11766434-B2 | Pyrimidinone derivatives as CDC7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-26 | — | — | US | disclosed |
| US-11760746-B2 | Methods and intermediates for preparing therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760746-B2 | Methods and intermediates for preparing therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760746-B2 | Methods and intermediates for preparing therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| EP-3752496-A1 | METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION | GILEAD SCIENCES, INC. (US) | 2020-12-23 | — | — | EP | disclosed |
| CN-112055712-A | Processes and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections | 吉利德科学公司 | 2020-12-08 | — | — | CN | disclosed |
| US-20200369647-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2020-11-26 | — | — | US | disclosed |
| US-20200369647-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2020-11-26 | — | — | US | disclosed |
| US-10696657-B2 | Methods and intermediates for preparing therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10696657-B2 | Methods and intermediates for preparing therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190300505-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2019-10-03 | — | — | US | disclosed |
| US-20190300505-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2019-10-03 | — | — | US | disclosed |
| WO-2019161280-A1 | METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION | GILEAD SCIENCES, INC. (US) | 2019-08-22 | — | — | WO | disclosed |
| WO-2018087527-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300505-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | CYP11A1, CYP11B1, CYP11B2 | UCHL1 3144/4885KLKB1 1456/4885HSP90AA1 2836/4885 |
| US-12122765-B2 | Methods and intermediates for preparing therapeutic compounds | CYP11A1, CYP11B1, CYP11B2 | UCHL1 3144/4885KLKB1 1456/4885HSP90AA1 2836/4885 |
| US-11766434-B2 | Pyrimidinone derivatives as CDC7 inhibitors | CDC7, CDK7, CDK17 | UCHL1 4264/4885KLKB1 1765/4885HSP90AA1 2747/4885 |
| US-10696657-B2 | Methods and intermediates for preparing therapeutic compounds | CYP11A1, CYP11B1, CYP11B2 | UCHL1 3144/4885KLKB1 1456/4885HSP90AA1 2836/4885 |
| US-20240101533-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | CYP11A1, CYP11B1, CYP11B2 | UCHL1 3144/4885KLKB1 1456/4885HSP90AA1 2836/4885 |
| US-20250100999-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | CYP11A1, CYP11B1, CYP11B2 | UCHL1 3144/4885KLKB1 1456/4885HSP90AA1 2836/4885 |
| US-11760746-B2 | Methods and intermediates for preparing therapeutic compounds | CYP11A1, CYP11B1, CYP11B2 | UCHL1 3116/4885KLKB1 1539/4885HSP90AA1 2703/4885 |
| US-20200369647-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | CYP11A1, CYP11B1, CYP11B2 | UCHL1 3144/4885KLKB1 1456/4885HSP90AA1 2836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.